Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.68)
# 815
Out of 4,708 analysts
95
Total ratings
54.72%
Success rate
6.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $64.69 | +39.13% | 14 | Dec 12, 2024 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $90.69 | -11.79% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $7.46 | - | 1 | Nov 14, 2024 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $447.50 | +7.26% | 19 | Nov 5, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $714.62 | +42.03% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $258.78 | +56.50% | 2 | Oct 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $50 | $56.84 | -12.03% | 8 | Oct 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $237.92 | -7.53% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $9.10 | +9.89% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $5.94 | +9.43% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $41.06 | +75.35% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Dec 12, 2024
Reiterates: Overweight
Price Target: $90
Current: $64.69
Upside: +39.13%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $90.69
Upside: -11.79%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $7.46
Upside: -
Vertex Pharmaceuticals
Nov 5, 2024
Reiterates: Overweight
Price Target: $480
Current: $447.50
Upside: +7.26%
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $714.62
Upside: +42.03%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $258.78
Upside: +56.50%
Bristol-Myers Squibb Company
Oct 18, 2024
Reiterates: Neutral
Price Target: $50
Current: $56.84
Upside: -12.03%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $237.92
Upside: -7.53%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $9.10
Upside: +9.89%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.94
Upside: +9.43%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $41.06
Upside: +75.35%